Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipovenos
- Development stage
- Phase 4
- Lead developer
- Fresenius Kabi
- Administration
- Intravenous
01
Overview
Lipovenos is a sterile, pyrogen-free lipid emulsion primarily used for parenteral nutrition, providing energy and essential fatty acids to patients unable to maintain normal oral intake. Its typical composition includes soybean oil, glycerol, and egg phospholipids, with some formulations also containing medium-chain triglycerides. It functions by delivering lipids that are metabolized similarly to physiological chylomicrons, releasing fatty acids and glycerol for energy production and cellular structure. In a research context, a '20% lipid/heparin' formulation of Lipovenos has been used to induce hyperlipidaemia to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis.
- Brand names
- LipovenosLipovenos 20%Lipovenos MCTLipovenos MCT/LCT
- Other names
- LipovenousLipovenoes MCT 20%
02
Targets
LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on Lipovenos.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipovenos.